Clovis Oncology 관리
관리 기준 확인 3/4
Clovis Oncology CEO는 Patrick Mahaffy, Apr2009 에 임명되었습니다 의 임기는 14.25 년입니다. 는 $ 14.56K 가치에 해당하는 회사 주식의 0.67% 직접 소유합니다. 14.56K. 경영진과 이사회의 평균 재임 기간은 각각 7.4 년과 14.3 년입니다.
주요 정보
Patrick Mahaffy
최고 경영자
n/a
총 보상
| CEO 급여 비율 | n/a |
| CEO 임기 | 14.3yrs |
| CEO 소유권 | 0.7% |
| 경영진 평균 재임 기간 | 7.4yrs |
| 이사회 평균 재임 기간 | 14.3yrs |
최근 관리 업데이트
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17
Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$252m |
| Jun 30 2022 | n/a | n/a | -US$263m |
| Mar 31 2022 | n/a | n/a | -US$258m |
| Dec 31 2021 | US$3m | US$739k | -US$265m |
| Sep 30 2021 | n/a | n/a | -US$299m |
| Jun 30 2021 | n/a | n/a | -US$310m |
| Mar 31 2021 | n/a | n/a | -US$336m |
| Dec 31 2020 | US$3m | US$721k | -US$369m |
| Sep 30 2020 | n/a | n/a | -US$370m |
| Jun 30 2020 | n/a | n/a | -US$385m |
| Mar 31 2020 | n/a | n/a | -US$413m |
| Dec 31 2019 | US$7m | US$719k | -US$400m |
| Sep 30 2019 | n/a | n/a | -US$400m |
| Jun 30 2019 | n/a | n/a | -US$396m |
| Mar 31 2019 | n/a | n/a | -US$377m |
| Dec 31 2018 | US$6m | US$689k | -US$368m |
| Sep 30 2018 | n/a | n/a | -US$321m |
| Jun 30 2018 | n/a | n/a | -US$291m |
| Mar 31 2018 | n/a | n/a | -US$366m |
| Dec 31 2017 | US$9m | US$636k | -US$346m |
| Sep 30 2017 | n/a | n/a | -US$365m |
| Jun 30 2017 | n/a | n/a | -US$370m |
| Mar 31 2017 | n/a | n/a | -US$324m |
| Dec 31 2016 | US$789k | US$224k | -US$349m |
보상 대 시장: US 시장에서 비슷한 규모의 회사에 비해 Patrick 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.
보상과 수익: Patrick 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Patrick Mahaffy (60 yo)
14.3yrs
테뉴어
US$2,639,083
보상
Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
| Executive VP & CFO | 7.3yrs | US$1.19m | 0.072% $ 1.6k | |
| Executive VP | 7.5yrs | US$1.20m | 0.068% $ 1.5k | |
| Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer | 7.9yrs | US$1.24m | 0.078% $ 1.7k | |
| Executive VP & Chief Scientific Officer | 3.8yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Human Resources | 6.8yrs | 데이터 없음 | 데이터 없음 |
7.4yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 관리: CLVS.Q 의 관리팀은 노련하고 경험 (평균 재직 기간 7.4 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
| Independent Director | 14.3yrs | US$260.00k | 0.041% $ 889.9 | |
| Independent Director | 14.5yrs | US$270.00k | 0.040% $ 875.1 | |
| Independent Director | 14.5yrs | US$270.00k | 0.17% $ 3.8k | |
| Independent Director | 14.5yrs | US$270.00k | 0.044% $ 953.2 | |
| Independent Chairman | 10.5yrs | US$287.50k | 0% $ 0 | |
| Independent Director | 14.5yrs | US$257.50k | 0.040% $ 872.7 | |
| Director | 2yrs | US$375.21k | 데이터 없음 | |
| Independent Director | 10.5yrs | US$259.58k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$257.50k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$255.00k | 0% $ 0 |
14.3yrs
평균 재임 기간
67yo
평균 연령
경험이 풍부한 이사회: CLVS.Q 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 14.3 년).